68
Views
31
CrossRef citations to date
0
Altmetric
CASE REPORTS

Successful Treatment of Disseminated Cerebritis Complicating Methicillin-resistant Staphylococcus aureus Endocarditis Unresponsive to Vancomycin Therapy with Linezolid

, , , , , & show all
Pages 222-225 | Received 07 Jan 2004, Accepted 14 Jan 2004, Published online: 08 Jul 2009

  • Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the US, Canada, Latin America, Europe and Western Pacific region for the SENTRY Antimicrobial Surveillance Programme, 1997–1999. Clin Infect Dis 2001; 32(2): S114–32.
  • Steinberg JP, Clark CC, Hackman BO. Nosocomial and community acquired Staphylococcus aureus bacteraemia from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996; 23: 255–9.
  • Falcone M, Carfagna P, Cassone M, et al. Staphylococcus aureus septicaemia in hospitalized non-neutropenic adult patients: a retrospective clinical and microbiological analysis. Ann Ital Med Intern 2002; 17: 166–72.
  • Anonymous from the Centres for diseases control and prevention. Community acquired methicillin resistant Staphylococcus aureus infections. Michigan MMWR 1981; 30: 185–7.
  • Layton MC, Hierholzer W Jr, Patterson JE. The evolving epidemiology of MRSA at a university hospital. Infect Control Hosp Epidemiol 1995; 16: 12–7.
  • Embil J, Ramotar K, Romance L, et al. MRSA in tertiary care institutions on the Canadian prairies 1990–1992. Infect Control Hosp Epidemiol 1994; 15: 646–51.
  • Herold BC, Immergluck LC, Maranan MC, et al. Community acquired methicillin resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279: 593–8.
  • Moreno F, Crisp C, Jorgensen JH, et al. Methicillin resistant Staphylococcus aureus as a community organism. Clin Infect Dis 1995; 21: 1308–12.
  • Salgado CD, Farr BM, Calfee DP. Community acquired methicillin resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131–9.
  • Centers for disease control and prevention. Four paediatric deaths from community acquired methicillin resistant Staphylococcus aureus-Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 1999; 48: 707–10.
  • Khan MA, Greig JR, Jayamohan J. Community acquired methicillin resistant Staphylococcus aureus brain abscess in an immunocompetent individual. Scand J Infect Dis 2000; 32: 423–4.
  • Stefani S, Varaldo PE. Epidemiology of MRSA in Europe. Clin Microbiol Infection 2003; 9: 1179–86.
  • Nicoletti G, Bonfiglio G, Bartoloni A, et al. Distribution and antibiotic resistance of isolates from lower respiratory tract and blood cultures in patients in 3 Italian intensive care units: 2-y comparison. International Journal of Antimicrobial Agents 2000; 15: 265–9.
  • Zanelli G, Sansoni A, Zanchi A, et al. Staphylococcus aureus nasal carriage in the community: a survey from central Italy. Epidemiology and Infection 2002; 129(2): 417–20.
  • Scudeller R, Leoncini O, Boni S, et al. MRSA carriage: the relationship between community and health care setting. a study in an Italian hospital. J Hosp Infection 2000; 46(3): 222–9.
  • Campanile F, Mato R, Messina C, et al. Molecular epidemiology of MRSA in Italy: clonal diffusion and evolution of polymorphysms in mec A and Tn 554 regions. In: Program and abstract of the 3rd ECC, Madrid: 2000; p. 85.
  • Francioli P. Central nervous system complications of infective endocarditis. In: Scheld WM, Whitley RJ, Durak DT, eds. Infections of the Central nervous system. New York: Raven press, Ltd; 1991. p. 515–59.
  • Shaikh ZHA, Peloquin CA, Ericsson CD. Successful treatment of vancomycin resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001; 33: 375–9.
  • Viale P, Pagani L, Cristini F, et al. Linezolid for the treatment of central nervous system infections in neurosurgical patients. Scand J Infect Dis 2002; 34(6): 456–9.
  • Marchese A, Schito GC. The oxazolidinones as a new family of antimicrobial agent. Clin Microbiol Infect 2001; 7(4): 66–74.
  • Bouza E, Munoz P. Linezolid: pharmacokinetic characteristic and clinical studies. Clin Microbiol Infect 2001; 7(4): 75–82.
  • Diekema DJ, Jones RN. Oxazolidone antibiotics. Lancet 2001; 358: 1975–82.
  • Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35: 1018–20.
  • Cedric J, Caillon J, Le Mabeque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51(4): 857–64.
  • Stratton CW, Reller LB. Serum dilution test for bactericidal activity. I. Selection of a physiological diluent. J Infect Dis 1997; 136: 187–95.
  • Reller LB. The serum bactericidal test. Rev Infect Dis 1986; 8: 803 /8.
  • Enright MC, Robinson AD, Randle G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002; 99(11): 7687–92.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.